NEW
Font size
WorksheetsBeyond Basics - Introduction to Plasma p-tau217 and AB1-42
Total questions: 7
Worksheet time: 4mins
Which of the following best describes the role of plasma p-tau217 in clinical practice?
It confirms diagnosis of frontotemporal dementia
It is a non-invasive marker that reflects brain tau pathology triggered by amyloid
It indicates the severity of cardiac amyloidosis
It directly measures brain volume loss
What does a low level of plasma Aβ1-42 typically indicate in the context of Alzheimer's pathology?
Healthy neuronal turnover
Reduced amyloid production in the brain
Early amyloid deposition in brain plaques
Tauopathy without amyloid involvement
At what stage in Alzheimer’s disease progression do plasma p-tau217 levels begin to rise?
After onset of dementia symptoms
During late-stage AD only
Several years after amyloid plaque formation
10–15 years before symptom onset, following amyloid accumulation
Through which mechanism does p-tau217 typically enter the bloodstream from the central nervous system?
Intestinal absorption
Direct neuronal release into blood
Leakage through the blood-brain barrier and glymphatic transport
Hepatic secretion
In real-world clinical settings, why might the p-tau217/Aβ1-42 ratio be helpful even if p-tau217 alone is statistically comparable?
It reduces test cost
It adds interpretive value in borderline cases
It is easier to perform in labs
It avoids the need for PET imaging
What is the source of plasma p-tau217 in Alzheimer’s disease?
Peripheral nerve endings
Hepatic tau secretion
Neuronal tau release due to phosphorylation
Endothelial tau synthesis
What is one major clinical advantage of using plasma p-tau217/Aβ1-42 over p-tau181?
Lower specificity for Alzheimer’s
Earlier and stronger association with amyloid PET positivity
Better detection of Parkinsonian disorders
Improved sensitivity to vascular changes
